Vycor Medical, Inc.
VYCO
$0.20
$0.0314.29%
OTC PK
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 31.85% | 30.79% | 17.56% | 8.82% | 1.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.85% | 30.79% | 17.56% | 8.82% | 1.31% |
| Cost of Revenue | 84.50% | 73.04% | 37.39% | 15.11% | 7.78% |
| Gross Profit | 25.69% | 25.68% | 15.22% | 8.12% | 0.61% |
| SG&A Expenses | 10.90% | 15.81% | 16.49% | 13.50% | 10.18% |
| Depreciation & Amortization | 0.85% | 1.71% | 2.58% | 3.47% | 2.60% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.05% | 21.71% | 18.21% | 12.54% | 8.81% |
| Operating Income | 196.97% | 127.14% | -376.92% | -122.69% | -811.54% |
| Income Before Tax | 92.38% | 56.43% | -13.64% | -69.57% | -113.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 92.38% | 56.43% | -13.64% | -69.57% | -113.82% |
| Earnings from Discontinued Operations | 37.50% | 47.22% | 98.33% | 96.97% | 23.81% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 91.47% | 56.25% | -7.37% | -53.66% | -107.84% |
| EBIT | 196.97% | 127.14% | -376.92% | -122.69% | -811.54% |
| EBITDA | 605.59% | 505.16% | -10.96% | -45.69% | -141.08% |
| EPS Basic | 35.44% | 22.29% | 0.75% | -7.38% | -22.48% |
| Normalized Basic EPS | 94.44% | 60.00% | -10.53% | -66.67% | -111.76% |
| EPS Diluted | 34.81% | 21.66% | 2.94% | -4.80% | -19.70% |
| Normalized Diluted EPS | 91.67% | 57.14% | 0.00% | -42.86% | -89.47% |
| Average Basic Shares Outstanding | 2.07% | 1.92% | 1.35% | 0.86% | 0.36% |
| Average Diluted Shares Outstanding | 6.12% | 5.98% | -2.27% | -2.75% | -3.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |